共 320 条
[1]
Drachman DB(2016)Myasthenia gravis Semin Neurol 36 419-424
[2]
Gilhus NE(2015)Myasthenia gravis: subgroup classification and therapeutic strategies Lancet Neurol 14 1023-1036
[3]
Verschuuren J(2018)Myasthenia gravis: from autoantibodies to therapy Curr Opin Neurol 31 517-525
[4]
Mantegazza R(2018)Treatment of myasthenia gravis Neurol Clin 36 311-337
[5]
Bernasconi P(1995)Leflunomide interferes with pyrimidine nucleotide biosynthesis Inflamm Res 44 317-322
[6]
Cavalcante P(2021)Leflunomide ameliorates experimental autoimmune myasthenia gravis by regulating humoral and cellular immune responses Int Immunopharmacol 93 107434-287
[7]
Farmakidis C(2011)Update 2011: leflunomide in rheumatoid arthritis—strengths and weaknesses Curr Opin Rheumatol 23 282-867
[8]
Pasnoor M(2019)Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial Clin Rheumatol 38 859-1998
[9]
Dimachkie MM(2019)Efficacy and safety of leflunomide in IgA nephropathy: a systematic review and meta-analysis Int Urol Nephrol 51 1987-281
[10]
Barohn RJ(1995)Leflunomide prevents the development of experimentally induced myasthenia gravis Int J Immunopharmacol 17 273-88